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Background: The malignant potential of tumour cells may be influenced by the molecular nature of KRAS
mutations being codon 13 mutations less aggressive than codon 12 ones. Their metabolic profile is also different,
with an increased anaerobic glycolytic metabolism in cells harbouring codon 12 KRAS mutations compared with
cells containing codon 13 mutations. We hypothesized that this distinct metabolic behaviour could be associated
with different HIF-1α expression and a distinct angiogenic profile.
Methods: Codon13 KRAS mutation (ASP13) or codon12 KRAS mutation (CYS12) NIH3T3 transfectants were analyzed
in vitro and in vivo. Expression of HIF-1α, and VEGF-A was studied at RNA and protein levels. Regulation of VEGF-A
promoter activity was assessed by means of luciferase assays using different plasmid constructs. Vascular network was
assessed in tumors growing after subcutaneous inoculation. Non parametric statistics were used for analysis of results.
Results: Our results show that in normoxic conditions ASP13 transfectants exhibited less
HIF-1α protein levels and activity than CYS12. In contrast, codon 13 transfectants exhibited higher VEGF-A mRNA and
protein levels and enhanced VEGF-A promoter activity. These differences were due to a differential activation of Sp1/
AP2 transcription elements of the VEGF-A promoter associated with increased ERKs signalling in ASP13 transfectants.
Subcutaneous CYS12 tumours expressed less VEGF-A and showed a higher microvessel density (MVD) than ASP13
tumours. In contrast, prominent vessels were only observed in the latter.
Conclusion: Subtle changes in the molecular nature of KRAS oncogene activating mutations occurring in tumour cells
have a major impact on the vascular strategy devised providing with new insights on the role of KRAS mutations on
angiogenesis.
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Ras proteins have been the subject of intense research as
signalling molecules in normal and neoplastic cells [1].
Yet, a complete understanding of their exact mode of ac-
tion is still to come. Among the three RAS genes (H-RAS,
KRAS and N-RAS) KRAS is the most commonly activated
in human tumours. Several lines of evidence suggest that
not only the presence or absence of a KRAS mutation but
its molecular nature influences tumour cell behaviour
[2,3]. A reduced transforming capacity of codon 13 muta-
tion as compared with codon 12 is observed in vitro and* Correspondence: gcapella@iconcologia.net
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reproduction in any medium, provided the orin vivo, with short latency times to tumour-appearance for
codon 12 KRAS overexpressing cells [4-6]. Moreover, our
previous results indicate that distinct mutations associate
with specific metabolic phenotypes, an increased anaerobic
glycolytic metabolism in cells containing codon 12 KRAS
compared with cells containing codon 13 mutations.
Switching to a glycolytic metabolism is a rapid adaptation
to hypoxia that can be related to HIF1α expression [7].
Perpetual blood vessel formation and remodelling (angio-
genesis) is a hallmark of cancer and a prerequisite for
three-dimensional tumour growth, invasion, and metastasis
[8]. Hypoxia, by inducing HIF-1α, promotes the expression
of VEGF-A, the main pro-angiogenic hypoxia-induced gene
[9]. However, oncogenes are also per se potent inductors
of angiogenesis [10]. Ras proteins are a paradigm forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to their involvement in the regulation of key pro and anti
angiogenic factors [11-14]. However, its cross-talk with
hypoxia-dependent signals is not so clear.
To gain further insight into the metabolic potential
and distinct aggressiveness of different activating KRAS
mutations, we examined the expression levels of HIF-1α
and VEGF-A in stable mutated 12 and 13 NIH3T3
transfectants. Our results in vivo and in vitro indicate
that the distinct KRAS mutations generated different
normoxic HIF-1α responses. Moreover, different VEGF-
A expression patterns were observed that are independ-
ent of the HIF-1α status but dependent upon ERKs





NIH3T3 cells were produced as previously described
[4,15], with plasmid DNA containing a KRAS minigene
with a G:C A:T mutation (CYS12) at the first position of
codon 12 (pMLK12), a G:C A:T mutation (ASP13) at the
second position of codon 13 (pMLK13), and a control
plasmid containing the expression vector alone (pMLneo).
pMLK12, pMLK13, and pMLKwt plasmids were a gift of
Dr. Manuel Perucho of the Burnham Institute at La Jolla,
CA. Levels of expression of the KRAS protein in the se-
lected clones used were similar [15].
Cell culture
Clones were cultured in DMEM supplemented with 20%
Fetal Calf Serum and 500 μg/ml of neomycin G418. Mu-
tations were verified by direct sequencing prior to the
initiation of every experiment.
Inhibitors incubation
Transfected cells cultured 12 hours in FCS deprivation
were incubated 15 minutes with the corresponding kinase
inhibitor maintaining FCS deprivation. PI3K inhibitor
LY294002 (15 μM), p44/42 ERKs inhibitors PD98859
(0.06 mM) or U0126 (20 μM) were obtain by Calbiochem,
Ca. Afterwards, next fifteen minutes cells were in contact
with FBS and without inhibitors. At the end of incuba-
tions, transfected cells were removed from the dishes and
we obtained proteins or mRNA as convinced.
Tumour model
Athymic male nu/nu Swiss mice (Charles River Laboratory,
Sta Perpetua, Spain) were injected subcutaneously (s.c.)
as previously described [4], according to the protocols ap-
proved by the Institutional Animal Care and Use Commit-
tee. Tumours were measured periodically with a calliper,
and the volume was calculated as length × width2 × 1/2[16]. Tumours were surgically removed and analysed when
they reached a diameter of ~ 1 cm.
Protein expression analysis
Western blotting
Cells and tissue samples were lysed with RIPA buffer (1%
SDS 10%, 1% NP40, 0.5% de Sodium deoxycholate) plus
protease inhibitors. Forty μg of each protein sample were
subjected to 10% SDS/PAGE under reducing conditions,
and transferred to polyvinylidene fluoride membranes
(PVDF-Bio-Rad, Hercules, CA). Membranes were blocked
in TBST buffer (0.9% NaCl, 0.02 M Tris (pH 7.5), 0.05%
Tween 20; 5% skimmed milk; 1 h, RT), and probed with
primary antibodies: anti-pan-Ras (Oncogene Research
Products San Diego CA mouse monoclonal clone RAS10
cat: OP40), anti-HIF-1α (a generous gift from Dr. Edurne
Berra, CICBiogune, Bilbao, Spain), anti-GLUT-1 (Abcam,
Cambridge, UK, ref. Ab652), anti-VEGF-A (Neomarkers,
CA, Ref. MS-35), anti-Sp1 (Santa Cruz, CA, ref. SC-59),
anti-p-ERKs (Sigma-Aldrich Inc. Monoclonal Anti-Map
Kinase activated clone MAPK-YT), anti-p-Akt (Cell
Signaling Rabbit Phospho-Akt (Ser473) antibody #9271)
and anti-Tubulin (Sigma-Aldrich Inc). Detection was
performed using peroxidase-conjugated secondary anti-
bodies. The resulting complexes were visualized by en-
hanced chemiluminiscence autoradiography (Amersham
Life Science,Chicago,Il). Autoradiographs were quantified
by scanning densitometry Quantity One Quantitation
Software™ (Bio-Rad, Hercules, CA).
Enzyme linked immunosorbent assay/ELISA
Expression levels of culture medium cells and tissue associ-
ated VEGF were also examined by enzyme linked immuno-
sorbent assay (ELISA: Quantikine immunoassay kits; R&D
Systems) according to the manufacturer’s instructions.
Vegf Immunohistochemistry
It was performed on paraffin-embedded tissues with VEGF
(C-1) mouse monoclonal antibody (Santa Cruz Biotechnol-
ogy Cat#sc-7269). We used anti-mouse DakoCytomation
EnVision System HRP to visualize the reaction.
RNA expression
Total RNA extraction and RT-PCR
Trizol Reagent (Life Technologies Gibco) according to
manufacturer’s instructions was used to total mRNA ex-
traction. One μg of RNA was reverse-transcribed into
cDNA using pdN6 primers using High Capacity Reverse
Transcriptase (Applied Biosystems, Foster city CA). Subse-
quent Real-Time PCR reaction for Vegf-A mRNA levels
was performed in duplo in the LightCyclerW System
SYBGreen480 (Roche) using primers: Rev: CAC
CTTCATGGGACTTCTGCT; Fwd: GCACTGGACC
CTGGCTTTA. Angpt2 mRNA levels were assessed in
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assays Mm00545822 (Applied Biosystem, Foster city
CA). Every gene expression quantification was corrected
using three housekeeping genes: mitochondrial ribo-
somal protein L19 Mn00452754; Hypoxanthine guanine
phosphoribonyl transferase 1 Mn01545399 and Pepti-
dylpropyl isomerase A Mn02342430. Threshold cycle
data were analyzed using the following formula: ratio =
((Etarget)
ΔCP target (control–sample)) [17].
Actinomycin D assay
Cellular clones were cultured in 12 well plates and
incubated 15, 30 and 180 minutes with Actinomycin D
(5 μg/ml) just before RNA total extraction was performed
using Trizol Reagent (Life Technologies Gibco) and fol-
lowing manufacturer’s protocol.
VEGF promoter plasmid transfections and luciferase
determination
NIH3T3 stable KRAS clones were transfected with three
different Vegf promoter constructions and a plasmid
containing multiple HRE inserts that were a kind gift of Dr.
Pages and Dra Berra [18-21]. Construct 1 contained the
complete Vegf Promoter, construct 2 lacked AP2 and Sp1
response elements and construct 3 lacked HRE elements.
Lipofectamine 2000 was used as the transfection agent
according to manufacturer’s instructions. (Invitrogen Life
Technologies S.A.). At 48 h post transfection, luciferase
expression was determined using the Dual Luciferase
Reporter System (Promega), and the relative luciferase
value was determined after normalizing to the β-Gal con-
trol. Results are expressed as mean of three independent
experiments.
Determination of DNA synthesis in HUVEC
HUVE cells (obtained from Advancell company) were
deprived of growth factors for 24 h in 199 medium
containing 0.1% Fetal Calf Serum. Cells were then stimu-
lated 48 h with conditioned growth media from the dif-
ferent NIH3T3 clones, containing 0.25 μCi/ml (6-3H)
thymidine (Amersham Pharmacia Biotech) (3 mM final
concentration). After 20 hours of incubation, the incor-
porated radioactivity was counted by liquid scintillation.
Results are expressed as a percentage of the (6-3H) thy-
midine incorporation in the presence of the medium of
control NIH3T3.
Ras activation assay
One mg of the protein lysate from ASP13 or CYS12
NIH3T3 cell clones was added to 30 μg of glutathione S-
transferase (GST)- RBD fusion protein. RBD, encompassing
amino acids 51 to 131 of Raf-1 protein, is the minimal do-
main required for the binding of Ras-GTP. Presence of ac-
tive Ras was detected by Western blotting with monoclonalanti-pan-Ras (Oncogene Research Products mouse mono-
clonal clone RAS10 cat: OP40). Autoradiography bands
were quantified by scanning densitometry using Quantity
One Quantitation Software™ (Bio-Rad Laboratories, S.A.,
Alcobendas, Madrid).
Assessment of vascular patterns
MicroVessel Density (MVD)
It was assessed using rat anti-PECAM (BD Pharmingene,
NJ USA 550274/MEC13.3) staining on cryopreserved sec-
tions. MVD was evaluated as mean of the number of ves-
sels in 5 hot spot fields at 400X. Only endothelial PECAM
staining was considered [22].
Double immunofluorescence was used to evaluate
Desmin(+)/PECAM(+). Rat anti-mouse monoclonal PEC-
AM (BD Pharmingene,NJ USA 550274/MEC13.3) and
rabbit anti-Desmin antibody (Lab Vision/NeoMarkers, CA,
USA; RB-9014) were simultaneously incubated overnight at
4°C. Secondary goat anti-rat Alexa 546 and anti-rabbit
Alexa 488 were incubated for 1 h. After washing, staining
was evaluated in five hot spot fields at 400X. LEICA soft-
ware counted the areas with Desmin and PECAM overlap-
ping staining and also measured major diameters of the
lumen of vessels. Correlation was performed with the pres-
ence of necrosis.
Immunohistochemistry
Rabbit anti α-Smooth muscle actin (Lab Vision/
NeoMarkers, CA, USA; RB-9010, ready to use) staining
was performed on paraffin-embedded tissue sections. En-
vision anti-rabbit (Dako Denmark A/S, Glostrup, DK) plus
diaminobenzidine were used to visualize the reaction.
Immunoreactivity was semiquantitatively evaluated by
comparing the level of expression between distinct groups.
Carbonic anhydrase IX (Ab15086,Abcam plc,. Cambridge,
UK) and GLUT-1 (Ab652; Abcam plc. Cambridge UK)
staining was also performed. Cytoplasmic positive cells
were expressed as a percentage of total cells counted. For
all antibodies, no staining was observed with negative con-
trol samples (absence of primary antibody, or incubation
with an irrelevant antibody or IgG).
Results
KRAS codon-specific mutations induce a distinct
HIF1-α and VEGF-A response
In normal cell culture conditions basal HIF-1α protein
levels were higher in CYS12 mutants compared with
ASP13 expressing cells or control NIH3T3 (Figure 1A).
As expected, these basal levels of HIF-1α in the different
clones analyzed increased when cells were subjected
to hypoxia (data not shown). In order to confirm that
HIF-1α protein was functional in our cells, we
transfected NIH3T3 and NIH3T3 KRAS mutants cells
(ASP13 or CYS12) with an extra DNA plasmid where
Figure 1 HIF-1α, GLUT-1 and VEGF-A in cultured KRAS ASP13
and CYS12 transfectants. A) HIF-1α protein expression was
measured by western blot in NIH3T3 control cells (0), three
independent clones KRAS CYS12 mutant (1, 2 and 3 show different
transfected clones) and two independent clones KRAS ASP13 mutant
(Clones 4 and 5). Tubulin was measured as a loading control.
B) Luciferase activity after transfection of HIF-1α-response element
promoter in NIH3T3, clone 3 KRAS CYS12 mutant and clone 4 KRAS
ASP13 mutant. Results are average ± SE of three independent
experiments. Activity in ASP13 mutants was significantly lower than in
CYS12 mutants (P < 0.05). C) Protein extracts were obtained from clone
4 KRAS ASP13 mutant and from clone 3 KRAS CYS12 mutant. GLUT-1,
VEGF-A and Tubulin (as a loading control) were immunodetected by
western blotting. A representative blot is shown. The electrophoretic
pattern of GLUT-1 depicts its glycosylation.
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sponse element (HRE). As shown in Figure 1B, a clear
correlation between HIF-1α protein levels and luciferase
activity – reflecting the quantity of HIF-1α attached to
the HRE [21] – existed. These findings suggest that the
transcription factor was functional in normoxic cells and
presented a higher activity in CYS12 KRAS cells.
Next, we decided to evaluate the impact of this differ-
ential expression on two HIF-1α-dependent genes,
GLUT-1 the ubiquitous glucose transporter protein, and
VEGF-A [9]. As observed in Figure 1C, and as expected
from its more glycolytic phenotype, CYS12 mutant cells
presented higher total levels of GLUT-1 as well as an in-
crease in the glycosylated forms [23], when compared
with ASP13 cells. Surprisingly, VEGF-A protein levels
were higher in ASP13 cells than in CYS12 (Figure 1C).
To confirm these differences, we analysed VEGF-A
mRNA levels in our cells. A 120% increase in mRNA levels
was observed in ASP13 cells compared with CYS12
transfectants (Figure 2A). Moreover, VEGF-A levels se-
creted in the cell culture medium were 11 times higher in
ASP13 cells compared with CYS12 (Figure 2B). Finally, this
VEGF-A was functional as addition of ASP13-transfectant
conditioned medium to HUVEC endothelial cells resulted
in higher thymidine incorporation (Figure 2C). These re-
sults suggest that KRAS ASP13 mutation activates a path-
way that may overpass regulation of VEGF-A by HIF-1α.
Mechanisms underlying the differential VEGF-A over
expression in ASP13 cells
The increased amount of VEGF-A mRNA observed in
ASP13 transfectants was not associated with differences in
mRNA stability, measured when actinomycin D was
added to the medium (Figure 3A). In contrast, activity of a
construct containing the first 1176 bp of the VEGF-A pro-
moter was 3 times higher in ASP13 cells compared to
CYS12 mutated clones (P < 0.02; Figure 3B Construct 1).
Together, these results indicated that differences between
cells were caused by different transcriptional activities of
the VEGF-A promoter.
Deletion of HRE within the VEGF-A promoter in all
clones did not affect its activity. (Figure 3B Construct 2 vs
Construct 1). These results further confirm the
HIF-1α independent regulation of VEGF-A expression. In
contrast, the selective deletion of SP1/AP2 response ele-
ments resulted in a significant decrease of VEGF promoter
activity in both transfectants that was only significant to
ASP 13 mutants (Figure 3B Construct 3 vs Construct 1).
AP2 and Sp1 are two transcription factors mainly con-
trolled by Ras-Raf-ERKs pathway activation. [24]. In
order to measure the pathway activity, we first measured
Ras protein activity levels able to stimulate the ERK cas-
cade. ASP13 clone showed an increased capacity to acti-
vate Raf (Figure 4A) that was associated with increased
Figure 2 Expression and activity of VEGF-A in KRAS
transfectants. A) VEGF-A mRNA levels were measured by RT-PCR in
ASP13 or CYS12 cells. Data are expressed as average ± S.E. of 2-ΔCT
(ASP13: 0.468 ± 0.12; CYS12: 0.253 ± 0.08; P = 0.07) B) VEGF-A protein
levels were measured by ELISA in conditioned media from NIH3T3
control cells, ASP13 and CYS12 transfectants (NIH3T3: 51.8 ± 3.9 pg
VEGF-A165/ml medium; ASP13: 630.69 ± 12.1 pg VEGF-A165/ml
medium; CYS12: 119.14 ± 6.9 pg VEGF-A165/ml medium) ASP13 cell
increase five times VEGF-A 165 protein expression than CYS12.
(P < 0.05). C) Conditioned media obtained from NIH3T3 control cells,
ASP13 and CYS12 transfectants was added to HUVEC cells cultured and
thymidine incorporation measured. Results are average ± S.E. of 3
independent experiments. The conditioned media from ASP13
transfectants increased HUVEC proliferation.
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served on PI3K cascade measured by pAKT levels.
Accordingly, when ERKs activity was inhibited with
U0126 for 15 minutes, a decay in mRNA VEGF-A levels
was observed in ASP13 clone that was not evident in
CYS12 (Figure 4C). No differences in total Sp1 protein
levels were observed in mutants clones ASP13 or CYS12
(Figure 4D). In all, these results indicate that Ras-Raf
-ERK-AP2/Sp1 signalling cascade is responsible for
VEGF-A overexpression in ASP13 cells.
To study if these differences detected in vitro could
cause a difference in the angiogenic patterns and tu-
moral capacity we subcutaneously injected NIH3T3 con-
trol cells and transfected clones (ASP13 or CYS12) in
nude mice. In agreement with our previous observations
latency period of tumors arising from distinct ASP13
transfectants was longer than for CYS12 tumors (ASP13
32.2 ± 8.9 days vs CYS12 10.4 ± 2.4; p < 0.04) (Table 1).
HIF-1α activity and hypoxia was assessed though immu-
nostaining of GLUT-1 and Carbonic Anhydrase IX. In
concordance with in vitro observations, GLUT-1 immu-
nostaining was more intense in CYS12 tumors albeit the
percentage of positive cells did not among the two
transfectants (Figure 5A). Differences in the expression
of Carbonic Anhydrase IX were more intense, being the
percentage of positive cells 4 times higher in CYS12
tumors (Figure 5B and C).
We confirmed that mRNA VEGF-A levels were also
higher in ASP13 tumours compared with CYS12 (Figure
6A). The same trend was observed at the protein VEGF-A
level, as assessed by ELISA and immunostaining (Figure 6B
and C). In contrast, angiogenic factor Angiopoietin 2 levels
did not show differences between tumours (Figure 6A).
Tumor growth vascular patterns
The distinct VEGF-A production observed was associ-
ated with a specific vascular pattern. On the one hand,
vascular hotspots zones with distended vessels were
apparent in ASP13 tumours, with generation of
haemorragic and necrosis zones (Figure 7A). On the
other hand, microvessel density (MVD) was higher in
CYS12 (Figure 7B), being the diameter of vessels
higher in ASP13 tumours (Figure 7C). Finally, vessels
from ASP13 tumours were surrounded by mural cells
that stained positive for α-Smooth Muscle Actin and
Desmin proteins, while mural cells were scarce around
CYS12 tortuous vessels (Figure 7D and E). These different
vascular patterns do not associate with significant
differences in the degree of necrosis among the two
transfectants.
Discussion
In the context of KRAS-driven tumourigenesis, mutations
located at codon 12 and 13 display distinct malignant
Figure 3 Functional analysis of VEGF-A PROMOTER. A) ASP13 or CYS12 cells were treated with actinomycin D. After the time indicated mRNA
was obtained and VEGF-A mRNA levels measured by RT-PCR. Results are the average of two independent experiments. No differences in VEGF-A
mRNA stability were observed in ASP13 or CYS12 cells. B) Luciferase activities after transfection of the complete VEGF-A promoter (Construct 1)
or two partial deletions (Construct 2 and 3). VEGF-A promoter activity was increased for all constructs in Asp13 when compared to CYS12
transfectants. Promoter activity was decreased after deletion of the AP2/Sp1 response elements in ASP13 cells (P < 0.011). Results are the average ± SE
of four independent experiments.
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[4,15], or metabolic profiles [25]. Here we show that minor
differences in the molecular nature of KRAS mutations
stimulate distinct intracellular signalling pathways in
normoxic conditions with different impact in basal levels
of HIF-1α VEGF-A production and generation of a dis-
tinct vascular network in tumours.
Upregulation of VEGF by the KRAS pathway has been
previously shown [26]. Here we show that cells expressing
ASP13 KRAS mutant present higher levels of VEGF-A,
the main pro-angiogenic gene induced by hypoxia, in the
absence of high HIF-1α levels [9]. In contrast, CYS12 mu-
tants present a high glycolytic phenotype [25] throughHIF-1α-dependent induction of glycolytic enzymes includ-
ing GLUT-1 glucose transporter supporting the role of
HIF-1α in switching to a glycolytic metabolism [7].
We have attempted to gain insight into the molecular
mechanisms underlying the differential VEGF-A overex-
pression, apparently independent of HIF-1α in ASP13
clones, Our data support a direct transcriptional effect of
ASP13 acting on VEGF-A promoter. This effect is mediated
by a distinct activation of Raf-ERKs pathway and AP2/Sp1
elements within the proximal VEGF-A promoter. Of note it
is independent of hypoxia-dependent elements and of PI3K
activity. Extracellular signals that induce VEGF-A through
this proximal region include, among others, growth factors
Figure 4 Signalling pathway activation analysis. A) Quantification of active Ras present in ASP13 and CYS12 cells. ASP13 transfectants showed
more Ras activation (P = 0.026). B) Analysis of p-ERKs, p-Akt and Tubulin (as a loading control) from ASP13 and CYS12 cells treated or not with
U0126 (specific inhibitor of MEK and in consequence of p-ERK) and LY294002 (specific inhibitor of PI3K and in consequence of p-Akt) is depicted.
p-ERKs levels were higher in ASP13 transfectants than CYS12, while no differences were observed in p-Akt levels. Representative western blots are
shown. C) mRNA VEGF-A levels as 2-ΔCT; ASP13 Control 0.40 ± 0.07; +LY294002 0.49 ± 0.1, +U0126 0.12 ± 0.04; CYS12 Control 0.08 ± 0.009,
+LY294002 0.05 ±0.02, +U0126 0.046 ± 0.02. Treatment with U0126 MEK inhibitor but not with PI3K inhibitor LY294002 resulted in a reduction of
mRNA VEGF-A levels in ASP13 transfectants (P = 0.031). D) Sp1 transcription factor levels were not different in ASP13 and CYS12 cells. Levels of
Sp1 and Tubulin (as a loading control) were assayed in extracts from NIH3T3 cells (N), different ASP 13 clones (4, 5, 6 and 7) and different CYS 12
clones (1, 2 and 3).
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glandin E2 in human muscle cells [27], M-CSF in mono-
cytes [28] and lysophosphatidic acid (LPA) in ovarian
cancer cells [29]. All of them affect promoter activity
through modulation of at least Sp1 transcriptional activity.
Noteworthy, Sp1 is also regulated by different signalling
pathways including ERKs, PKA and PI3K-Akt [18,30]. We
have not detected changes in total Sp1 protein levels be-
tween ASP13 and CYS12 mutants, but other mechanisms
with impact in the activity of this transcription factor could
be implicated, such as acetylation, sumoylation, glycosyla-
tion or phosphorylation [24].
In our xenograft model, ASP13 xenografts consistently
develop angiogenic sprouts of large diameter, invested by
mural cells. These structures seem to be sufficient toTable 1 Differences in latency period in vivo between ASP13
ASP13
Clone 4 (n = 10) Clone 6 (n = 10) Clone 2 (n = 10) Clo
Days ± SD 30,1 ± 6,5 24,5 ± 6,1 42 ± 0
Mean ± SD 32.2 ± 8.9support the increased utilization of the oxidative pentose
phosphate pathway observed in the more benign ASP13 tu-
mours [25]. While development of these complex vascular
structures may account for the initial delay observed in
tumour growth, we speculate that they are able to support
the very rapid growth occurring later [4]. Nonetheless, the
presence of significant tumour necrosis and less Carbonic
anhydrase IX to hypoxic adaptation, observed in established
ASP13 tumours may depict the relative insufficiency of this
vascular tree [8]. In contrast, histological analysis reveals
that the more aggressive CYS12 tumours educe a dense
endothelial-lined microvascular network that allows an
early, steady and sustained tumour growth. This vascular
strategy appears to be effective for these tumour cells that
are more resistant to hypoxia, do not proliferate fast [31]and CYS12 transfectants
CYS12
ne 5 (n = 10) Clone 4.3 (n = 10) Clone 4.6 (n = 10)
9,7 ± 7,9 8.4 ± 0.9 13,2 ± 1,7
10.4 ± 2.4 P < 0.04
Figure 5 GLUT-1 and Carbonic anhydrase IX immunostaining in
KRAS ASP13 and CYS12 tumours. A) The percentage of GLUT-1
positive cells did not differ in CYS12 and ASP13. Intensity was higher
in CYS12 tumors. B) The percentage of Carbonic anhydrase IX
positive cells and the intensity of the immunostaining is higher in
CYS12 tumors. C) Table depicts the percentage of Carbonic
anhydrase positive cells. ASP13: 11.67 ± 3.07% vs CYS12:
48.57 ± 7.9%; P < 0.002).
Figure 6 VEGF-A expresion in KRAS ASP13 and CYS12 tumours.
A) VEGF-A mRNA and Angiopoietin-2 levels detected by real time
PCR in tumour tissue. VEGF-A was overexpressed in ASP13 tumours
when compared with CYS12 (ASP13: 0.9 ± 0.2 2-ΔCT vs CYS12: 0.4 ±
0.1 2-ΔCT; P = 0.04) while mRNA Angiopoietin-2 levels were not
different. B) VEGF-A protein levels measured by ELISA were shown
as pg of VEGF per mg of tumour lysate. VEGF-A were higher in
ASP13 tumours (ASP13: 5.5 ± 0.98 μg VEGF-A/mg tumour lysate vs
CYS12: 2.5 ± 0.6 μg VEGF-A/mg tumour lysate; P = 0.02). C) Illustrative
VEGF-A immunostaining is shown for each mutant.
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with an increased anaerobic glycolysis.
The vascular pattern observed in ASP13 xenografts is
in line with previous observations linking high VEGF-A
levels with an increased diameter of newly forming ves-
sels [32,33]. The prominent stimulation of DNA synthe-
sis in primary HUVECs by whole ASP13 conditioned
medium, and in a less conspicuous manner by CYS12
supernatants, propose significant paracrine effects of
tumour cell-derived VEGF-A in neovascularization [34].
Also, ASP13 tumours vessels are covered with α-Sma
(+)/Desmin(+) cells [35] further highlighting the contribu-
tion of VEGF-A to vessel maturation and tumour growth.
The retarded growth of ASP13 tumours harbouring ele-
vated VEGF-A levels is consistent with reports challenging
Figure 7 Vessel number in ASP13 and CYS12 subcutaneous tumours. A) PECAM immunohistochemistry (up) and PECAM immunofluorescence
(bottom) staining of subcutaneous tumours are shown as a representative example of each tumour mutation group. (ASP13 on the left and CYS12 on
the right). B) Microvessel density (MVD) was represented as number of vessels structures PECAM+/microfield at 400X. (CYS12 40.8 ± 8 vs ASP13 23.7 ± 6
number of PECAM (+) vessels; P = 0.002). C) Mean of vessel diameter is shown in each bar. (ASP13: 96,4 ±12,9 μm vs CYS12: 19.3 ± 2.8 μm; P < 0.0001).
D) Representative staining of ASP13 (left) and CYS12 (right) tumour tissues are shown. Up: αSMA of paraffin tumour tissue. Bottom: PECAM/Desmin
staining on cryopreserved tumour tissue. Positive mural cells were more evident in ASP13 tumours. E) PECAM/Desmin ratio analysed by LEICA software
was represented. Ratio was higher in ASP13 tumours (P < 0.0001).
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tor. While angiopoietin2 levels did not show differences
between transfectants, we cannot exclude a role of other
angiogenic factors in differences observed between ASP13
and CYS12 tumoral vessels [36].
The impact of the genetic background of tumour cells on
the angiogenic phenotype is relevant since they may have
consequences regarding efficacy of specific antiangiogenic
strategies. An evolving tumour with an ever-changing gen-
etic background likely educes a dynamic vascular strategy
that may escape to specific antiangiogenic treatment such
as those targeting VEGFRs or its ligand [37]. This is of im-
portance now that more antiangiogenic drugs are being in-
troduced to the clinical setting and there is a need for
biomarkers that help in the selection of patients to be
treated. KRAS mutations are used as negative predictors of
antiEGFR therapies in colorectal cancer [38]. The role of
KRAS mutation as a predictive marker of bevacizumab-
based treatment has been also explored. Indeed, better re-
sponse rates to bevacizumab can be observed in KRAS wt
colorectal tumors when compared to KRAS mutant [39].
Of note, some authors have explored a potential differential
behaviour of codon 13 mutant tumors with no conclusive
results [40]. It will of interest to explore in the adequateclinical setting whether our experimental observations cor-
relate with clinical outcome in other tumor types such as
colorectal cancer.Conclusions
Mutations in the KRAS gene are among of the most
prevalent in human tumours and they are known to have
pleiotropic effects on tumour biology. The less aggressive
ASP13 mutation, through Raf-Ras-ERKs activation of the
VEGF-A promoter, creates a prominent VEGF-A-associ-
ated vascular network in the absence of high HIF-1α
levels. This vascularisation is less effective than the dense
microvascular network observed in CYS12 tumours. In
our model system, we have shown that the molecular na-
ture of KRAS mutations clearly influences the vascular
strategy devised by the tumour cell. These observations
provide us with a deeper insight of the complex role of
major angiogenic regulators such as VEGF on tumour vas-
culature development and their relationship with onco-
gene activation.
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